Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status ...
John R. Hurst, MD, PhD, explains how BEAM-302 gene editing targets both lung and liver disease in alpha-1 antitrypsin ...
Patients with ≥5 impaired domains experienced markedly worse outcomes versus none, including >2-fold higher mortality and ...
In addition, Godara noted that toxicity management for bispecific antibodies has evolved. While early use of these therapies ...
Concurrent guideline statements have increased classification ambiguity, strengthening arguments for phenotype-first ...
New York’s $76M emphasizes rural care coordination via partnerships and integrated health networks to reduce fragmentation between hospitals, primary care, and community resources. CMS awarded NY, RI, ...
Francesca Puggioni, MD, explains how multidisciplinary teams choose COPD biologics and why systemic inflammation matters as much as FEV1. Multidisciplinary approaches, particularly when treating ...
1. ZANVASTRO (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) ...
Allocation frameworks do not prohibit age but label 65-70 as higher risk and >70 as high risk, while scoring systems may favor older candidates due to greater waitlist mortality. Pediatric indications ...
A separate poster, drawing on data from the National Institutes of Health's All of Us Research Program, found that women with ...
US mortality surveillance mirrors the relative burden: 141,733 COPD deaths in 2023 outnumbered prostate and breast cancer ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results